n.a. (BPAX)

55.05
0.69 1.24
NASDAQ
Prev Close 55.74
Open 56.64
Day Low/High 54.22 / 56.64
52 Wk Low/High 12.79 / 56.99
Volume 182.41K
Exchange NASDAQ
P/E Ratio N/A
Div & Yield N.A. (N.A)
BioSante Pharmaceuticals Alert: The Briscoe Law Firm And Powers Taylor, LLP Investigate Possible Breaches Of Fiduciary Duty By The Officers And Directors Of BioSante Pharmaceuticals, Inc.

BioSante Pharmaceuticals Alert: The Briscoe Law Firm And Powers Taylor, LLP Investigate Possible Breaches Of Fiduciary Duty By The Officers And Directors Of BioSante Pharmaceuticals, Inc.

Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation firm of Powers Taylor, LLP announce that the firms are...

BioSante Pharmaceuticals Announces Positive Pill-Plus™ Data Presentation

BioSante Pharmaceuticals Announces Positive Pill-Plus™ Data Presentation

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) announced today that data from studies of the Pill-Plus “triple component” oral contraceptive were presented on March 10, 2012 by Pantarhei Bioscience at the World ...

BioSante Pharmaceuticals Reports Financial Results For 2011 And Corporate Highlights

BioSante Pharmaceuticals Reports Financial Results For 2011 And Corporate Highlights

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced financial results for the year ended December 31, 2011 and additional corporate highlights.

BioSante Pharmaceuticals, Inc. To Present At Roth Health Care Conference

BioSante Pharmaceuticals, Inc. To Present At Roth Health Care Conference

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that Stephen M.

BioSante’s Prostate Cancer Vaccine Resulted In Stable Disease In Over 50% Of Patients In Newly Published Study

BioSante’s Prostate Cancer Vaccine Resulted In Stable Disease In Over 50% Of Patients In Newly Published Study

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced publication of results from a Phase I dose escalation clinical study that show its GVAX Prostate cancer vaccine in treating metastatic castration-resistant...

Biotech Twitter Mailbag: Gilead, Chelsea, Keryx, Onyx, BioSante, Dendreon

Biotech Twitter Mailbag: Gilead, Chelsea, Keryx, Onyx, BioSante, Dendreon

Biotech columnist Adam Feuerstein responds to biotech stock questions posed by his Twitter followers.

Transocean, Netflix, BioSante Are Market Movers

Transocean, Netflix, BioSante Are Market Movers

Transocean, Netflix, BioSante, SodaStream are among big market movers Friday

BioSante’s Pancreas Cancer Vaccine Shows Over 60% Survival Increase In Newly Presented Study

BioSante’s Pancreas Cancer Vaccine Shows Over 60% Survival Increase In Newly Presented Study

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced presentation of results from a Phase Ib clinical study that show its GVAX Pancreas cancer vaccine increased the median survival of pancreatic cancer...

BioSante Pharmaceuticals, Inc. To Present At Citi 2012 Global Health Care Conference

BioSante Pharmaceuticals, Inc. To Present At Citi 2012 Global Health Care Conference

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that Stephen M.

Biotech Stock Mailbag: Vivus, Chelsea, BioCryst

Biotech Stock Mailbag: Vivus, Chelsea, BioCryst

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

BioSante: A Penny Stock Still Overvalued

BioSante: A Penny Stock Still Overvalued

Day traders are propping up BioSante's valuation. At some point, the numbers start to matter.

BioSante Exchanges $4 Million Aggregate Principal Amount Of Convertible Senior Notes For 4.5 Million Shares Of Common Stock

BioSante Exchanges $4 Million Aggregate Principal Amount Of Convertible Senior Notes For 4.5 Million Shares Of Common Stock

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), announced today that the company has entered into a privately-negotiated securities exchange agreement with a holder of BioSante’s 3.

BioSante Pharmaceuticals Announces FDA Approval For Bio-T-Gel™

BioSante Pharmaceuticals Announces FDA Approval For Bio-T-Gel™

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that the U.

BioSante Pharmaceuticals, Inc. To Present At BIO CEO & Investor Conference

BioSante Pharmaceuticals, Inc. To Present At BIO CEO & Investor Conference

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that Stephen M.

BioSante Pharmaceuticals Reports Positive LibiGel® Safety Data Review For Phase III Program

BioSante Pharmaceuticals Reports Positive LibiGel® Safety Data Review For Phase III Program

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), announced today that the independent Data Monitoring Committee (DMC) has completed the eighth unblinded review of the LibiGel Phase III cardiovascular and breast cancer...

BioSante Exchanges $5 Million Aggregate Principal Amount Of Convertible Senior Notes For 6.7 Million Shares Of Common Stock

BioSante Exchanges $5 Million Aggregate Principal Amount Of Convertible Senior Notes For 6.7 Million Shares Of Common Stock

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), announced today that the company has entered into a privately-negotiated securities exchange agreement with a holder of BioSante’s 3.

6 Drug Stocks Unworthy of Biotech Bull Market

6 Drug Stocks Unworthy of Biotech Bull Market

The biotech sector is having a party but not all stocks deserve invites. Here's a list of over-valued or undeserving biotech stocks.

Biosante Stock Falls On Unusually High Volume (BPAX)

Biosante Stock Falls On Unusually High Volume (BPAX)

Biosante Pharmaceuticals (Nasdaq:BPAX) is trading at unusually high volume Tuesday with 21 million shares changing hands. It is currently at 4.2 times its average daily volume and trading down 10 cents (-9.5%).

BioSante Pharmaceuticals Provides Corporate Update

BioSante Pharmaceuticals Provides Corporate Update

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced a corporate update.

The Law Firm Of Levi & Korsinsky, LLP Launches An Investigation Into Possible Securities Laws Violations By BioSante Pharmaceuticals, Inc.

The Law Firm Of Levi & Korsinsky, LLP Launches An Investigation Into Possible Securities Laws Violations By BioSante Pharmaceuticals, Inc.

Levi & Korsinsky is investigating potential claims on behalf of purchasers of BioSante Pharmaceuticals, Inc.

Biotech Stock Live Chat: 2012 Preview

Biotech Stock Live Chat: 2012 Preview

TheStreet's biotech columnist Adam Feuerstein is holding a live, interactive discussion about biotech stock investing.

Market Preview: The Year Without a Santa Claus Rally

Market Preview: The Year Without a Santa Claus Rally

The chance of a big push higher to finish the year grows dimmer by the day. In the video, Chao Deng recaps the trading day.

Novellus, BioSante: After-Hours Trading

Novellus, BioSante: After-Hours Trading

Shares of Novellus Systems jump after the company agrees to be acquired by Lam Research for $3.3 billion in stock.

Biosante Stock Falls On Unusually High Volume (BPAX)

Biosante Stock Falls On Unusually High Volume (BPAX)

Biosante Pharmaceuticals (Nasdaq:BPAX) is trading at unusually high volume Wednesday with 7.4 million shares changing hands. It is currently at 4.3 times its average daily volume and trading down 39 cents (-15.5%).

BioSante Pharmaceuticals Announces Results From LibiGel® Efficacy Trials

BioSante Pharmaceuticals Announces Results From LibiGel® Efficacy Trials

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced top-line results from its two pivotal Phase III LibiGel (testosterone gel) efficacy trials.

BioSante Pharma Readying Release of 'Female Viagra' Study Results

BioSante Pharma Readying Release of 'Female Viagra' Study Results

Results from late-stage studies of BioSante's Libigel are expected this afternoon or tomorrow morning.

BioSante Pharmaceuticals Announces Issuance Of New LibiGel® Method Of Use Patent

BioSante Pharmaceuticals Announces Issuance Of New LibiGel® Method Of Use Patent

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced the issuance of a new U.

22 Hot Drugs Facing FDA Approval in 2012

22 Hot Drugs Facing FDA Approval in 2012

These are the biotech and drug stocks facing key FDA drug approval decisions in 2012.

BioSante Pharmaceuticals Added To NASDAQ Biotechnology Index

BioSante Pharmaceuticals Added To NASDAQ Biotechnology Index

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that it has been added to the NASDAQ Biotechnology Index® (Symbol: NBI), effective prior to the stock market open today, November 21, 2011.